The expression and clinical significance of transforming growth factor β1 (TGF-β1) and matrix metalloproteinase-2 (MMP2) in human renal clear cell carcinoma (RCCC) were investigated. The intensity of TGF-β1 and MMP2 expression in RCCC kidneys was significantly higher than that in normal kidneys. Expression of TGF-β1 and MMP2 in RCCC tissues was positively correlated with pathological grade and clinical stage. There was also a significant correlation between TGF-β1 and Msshese analyses indicate that upregulation of TGF-β1 and MMP2 expression may occur during the progression of RCCC. Thus, TGF-β1 and MMP2 may be useful molecular markers for evaluating prognosis in RCCC patients.
Zhao W., Kobayashi M., Yuan L., et al. Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II. Cancer Immunol Immunother. 2002;51:381-388.
2.
Huntley SP, Davies M., Matthews JB, et al. Attenuated type II TGF-beta receptor signaling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination. Int J Cancer . 2004;110:170-176.
3.
Yamamura T., Nakanishi K., Hiroi S., et al. Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. Lung Cancer. 2002;35:249-255.
4.
Sela BAMatrix metalloproteinase: promoters of tumor progression and invasiveness . Isr Med Assoc J. 2002;4:280-282.
5.
Ibrahim EC, Allory Y., Commo F., Gattegno B., Callard P., Paul P.Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma . Am J Pathol. 2003;162:501-508.
6.
Miyazono K.TGF-beta/SMAD signaling and its involvement in tumor progression. Biol Pharm Bull. 2000;23: 1125-1130.
7.
Pasche B.Role of TGF-β in cancer. J Cell Physiol. 2001;186:153-168.
8.
Tjiong MY, van der Vange N., ter Schegget JS, Burger MP, ten Kate FW, Out TACytokines in cervicovaginal washing fluid from patients with cervical neoplasia . Cytokine. 2001;14:357-360.
9.
Lang F., Klingel K., Wagner CA, et al. Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy. Proc Natl Acad Sci USA . 2000;97:8157-8162.
10.
Julie AM, James JK, Vivian M., et al. Invasion and metastasis of a mammary tumor involves TGF-β signaling. Int J Cancer. 2001;91:76-82.
11.
Kirimca F., Sarioğlu S., Kamsari C., Kavukçu S.Expression of CD44 and major histocompatibility complex II antigens correlate with renal scarring in primary and systemic renal diseases. Scand J Urol Nephrol. 2001;35:509-514.
12.
Edwards JG, McLaren J., Jones JL, Waller DA, O’Byrne KJMatrix metalloproteinases2 and 9(gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer. 2003;88:1553-1559.
13.
Mook OR, Frederiks WM, Van Noorden CJThe role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta. 2004;1705:69-89.
14.
Patel BP, Shah PM, Rawal UM, et al. Activation of MMP-2 and MMP-9 in patients witll oral squamous cell carcinoma. J Surg Oncol. 2005;90:81-88.
15.
Fukata S., Inoue K., Kamada M., et al. Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ specific metastasis of renal cell carcinoma . Cancer. 2005;103:931-942.
16.
Malhotra S., Newman E., Eisenberg D., et al. Increased membrane type 1 matrix metalloproteinase expression from adenoma to colon cancer: a possible mechanism of neoplastic progression . Dis Colon Rectum. 2002;45:537-543.
17.
Di Nezza LA, Misajon A., Zhang J., et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer. 2002;94:1466-1475.
18.
Huang X., Lee C.From TGF-beta to cancer therapy. Curr Drug Targets. 2003;4:243-250.
19.
Logullo AF, Nonogaki S., Miguel RE, et al. Transforming growth factor beta1 (TGFbeta1) expression in head and neck squamous cell carcinoma patients as related to prognosis. J Oral Pathol Med. 2003;32:139-145.
20.
Fang J., Shing Y., Wiederschain D., et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA. 2000;97:3884-3889.
21.
Ivaska J., Heino J.Adhesion receptors and cell invasion: mechanisms of integrin-guided degradation of extracellular matrix. Cell Mol Life Sci. 2000;57:16-24.
22.
Deryugina EI , Bourdon MA, Jungwirth K., Smith JW, Strongin AYFunctional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase . Int J Cancer. 2000;86:15-23.
